Stockscreener 앱 받기
1.80
9.55%
-0.19
시간 외 거래:
1.79
-0.01
-0.56%
전일 마감가:
$1.99
열려 있는:
$1.99
하루 거래량:
884.05K
Relative Volume:
1.60
시가총액:
$162.51M
수익:
$7.05M
순이익/손실:
$-30.43M
주가수익비율:
-4.7518
EPS:
-0.3788
순현금흐름:
$21.84M
1주 성능:
+16.88%
1개월 성능:
+52.54%
6개월 성능:
-49.72%
1년 성능:
-10.45%
1일 변동 폭
$1.79
$2.015
1주일 범위
$1.53
$2.015
52주 변동 폭
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
PRQR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.80 | 162.51M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
ProQR Therapeutics N.V (NASDAQ: PRQR) Posted 2.58% Gain This Year: What’s Next? - Stocksregister
JPMorgan Chase & Co. Has $142,000 Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Evercore ISI Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Boothbay Fund Management LLC Acquires 153,573 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Analysts Offer Predictions for PRQR FY2025 Earnings - MarketBeat
ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
ProQR Therapeutics NV expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ProQR Announces Webcast of Presentation at the 2025 Citizens Lif - GuruFocus
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference | PRQR Stock News - GuruFocus
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference - GlobeNewswire
RNA Editing Pioneer ProQR to Showcase Breakthrough Axiomer Platform at Major Healthcare Conference - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Earns Outperform Rating from Analysts at Evercore ISI - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Research Coverage Started at Cantor Fitzgerald - Defense World
Adage Capital Partners GP L.L.C. Purchases 5,976,813 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 - GlobeNewswire
ProQR Therapeutics N.V [PRQR] Investment Appeal on the Rise - knoxdaily.com
RNA Editing Market Deep Research 2025-2032 | QIAGEN N.V., ProQR - openpr.com
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - Nasdaq
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance
ProQR Therapeutics initiated with an Outperform at Evercore ISI - Yahoo Finance
XTX Topco Ltd Takes $163,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - The AM Reporter
Riding the Waves: A Guide to Investing in PRQR Stock - investchronicle.com
ProQR Therapeutics (PRQR) Receives Overweight Rating and $8 Pric - GuruFocus
Cantor Fitzgerald sets $8 price target on ProQR shares with Overweight rating - Investing.com
ProQR Therapeutics (PRQR) Gains Outperform Rating from Evercore ISI | PRQR Stock News - GuruFocus
Evercore ISI sets ProQR stock Outperform with $5 target By Investing.com - Investing.com UK
ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update - MarketBeat
Walleye Capital LLC Buys New Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics N.V (PRQR)’s Market Momentum: Closing Strong at 1.54, Up 6.21 - DWinneX
A new trading data show ProQR Therapeutics N.V (PRQR) is showing positive returns. - Sete News
Altium Capital Management LLC Takes $1.52 Million Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Citizens JMP reiterates ProQR stock with $8 target By Investing.com - Investing.com Nigeria
Can you now get a good deal on ProQR Therapeutics N.V’s shares? - uspostnews.com
Citizens JMP reiterates ProQR stock with $8 target - Investing.com
ProQR Therapeutics N.V (PRQR) Stock: A Year of Highs and Lows in the Market - investchronicle.com
ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Affinity Asset Advisors LLC Makes New Investment in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of “Buy” by Brokerages - Defense World
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):